Clinicopathological data of BRAF-altered cases
| ID | Path dx (grade) | BRAF alteration | Site | Adjuvant therapy | Follow-up (months) | Relapse (#) | Relapse interval (months) | Outcome |
| 1 | GG (low) | V600E | Hemisphere mesial temporal | None | 10.0 | None | None | SD |
| 2 | DLGG, MAPK (low) | KIAA1549::BRAF | Cerebellum | None | 25.4 | None | None | SD |
| 3 | PA (low) | KIAA1549::BRAF | Cerebellum | None | 12.3 | None | None | Alive NOS |
| 4 | PA (low) | KIAA1549::BRAF | Thalamus | Vincristine, carboplatin | 82.1 | 2 | 48, 81 | PD |
| 5 | PA (low) | KIAA1549::BRAF | Cerebellum | None | 33.8 | 1 | 20 | Alive NOS |
| 6 | PA (low) | KIAA1549::BRAF | Cerebellum | None | 17.8 | None | None | SD |
| 7 | PA (low) | KIAA1549::BRAF | Consider cerebellum | None | 20.1 | None | None | Alive NOS |
| 8 | PA (low) | KIAA1549::BRAF | Cerebellum | None | 8.5 | None | None | LFU |
| 9 | PA (low) | V600E | Hypothalamus | Vincristine, carboplatin | 11.1 | 1 | 10.8 | SD |
| 10 | DLGG, MAPK (low) | V600E | Midbrain | None | 20.0 | None | None | Alive NOS |
| 11 | PXA (low) | V600E | Hemisphere parietal | None | 141.6 | None | None | Alive NOS |
| 12 | PA (low) | V600E | Medulla | RT | 46.2 | None | None | DOD |
| 13 | DLGG, MAPK (low) | V600E | Hemisphere parietal | RT | 15.3 | 3 | 3.1, 10.2, 14.2 | DOD |
| 14 | PA (low) | KIAA1549::BRAF | Cerebellum | None | 12.5 | None | None | Alive NOS |
| 15 | PXA (low) | V600E | Hemisphere cortical parietal | None | 21.5 | None | None | LFU |
| 16 | PLNTY (low) | V600E | Hemisphere temporal | None | 51.3 | None | None | Alive NOS |
| 17 | PLNTY (low) | V600E | Hemisphere temporal | None | 105.7 | 1 | 72 | Alive NOS |
| 18 | LGG features of PA, H3 K27M, V600E (low)* | V600E | Thalamus | RT, temozolomide | 11.2 | None | None | LFU |
| 19 | PLNTY (low) | V600E | Hemisphere cortical temporal | None | 79.0 | 1 | 48 | NED |
| 20 | HGG NOS, IDH-WT, V600E (high)* | V600E | Hemisphere lateral ventricle/temporal | RT, temozolomide | 45.6 | 2 | 9.8, 43.6 | SD |
| 21 | GBM, epithelioid (high) | V600E | Hemisphere temporal | RT | 16.3 | None | None | DOD |
| 22 | GG (low) | V600E | Hemisphere temporal | None | 71.0 | 1 | 54 | SD |
| 23 | ODG (high) | K483E | Hemisphere parietal | RT, temozolomide | 175.5 | 3 | 78, 97.4, 158.3 | DOD |
| 24 | GBM (high) | Amplification | Hemisphere parietal | RT, temozolomide, bevacizumab | 45.6 | 1 | 12.2 | PD |
| 25 | Astrocytoma (high) | Amplification | Hemisphere temporal | RT, temozolomide | 19.3 | None | None | LFU |
| 26 | GBM (high) | Amplification | Hemisphere frontal | RT, temozolomide | 22.3 | None | None | LFU |
| 27 | GBM (high) | K601E | Hemisphere temporal | RT, temozolomide, Bevacizumab | 23.3 | 1 | 16.2 | PD |
| 28 | GBM, epithelioid (high) | V600E | Hemisphere temporal | RT, temozolomide, bevacizumab | 31.4 | 1 | 19.2 | DOD |
| 29 | PXA (high) | V600E | Hemisphere temporal | RT, temozolomide | 31.5 | 1 | 31.5 | PD |
| 30 | HGG, hemispheric, H3 K27M, BRAF-amp (high)* | Amplification | Hemisphere mesial temporal | RT, temozolomide, bevacizumab | 37.5 | 1 | 18.2 | LFU |
| 31 | GBM, epithelioid (high) | V600E | Hemisphere parietal | RT, temozolomide | 38.3 | 1 | 28.4 | LFU |
| 32 | GBM (high) | Amplification | Hemisphere frontal/ parietal/ temporal | None | 1.0 | None | None | LFU |
*Not defined in the 2021 WHO book.
DOD, died of disease; GBM, glioblastoma; GG, ganglioglioma; HGG, high-grade glioma; LFU, lost to follow‐up; LGG, low-grade glioma; DLGG, MAPK, diffuse low-grade glioma MAPK pathway-altered; NED, no evidence of disease; Alive NOS, alive not otherwise specified; ODG, oligodendroglioma IDH-mutant 1 p/19q-codeleted; PA, pilocytic astrocytoma; PD, progressive disease; PLNTY, polymorphous low-grade neuroepithelial tumour of the young; PXA, pleomorphic xanthoastrocytoma; RT, radiation therapy; SD, stable disease.